Tag Archives: Viekira Pak

December, 2016

April, 2016

  • 25 April

    FDA Expands Approval of AbbVie’s Viekira Pak for Use without RBV

    NORTH CHICAGO, Ill., April 25, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in …

February, 2016

January, 2016

December, 2015

  • 2 December

    Hepatitis C Deaths Still On Rise

    The headlines are compelling when it comes to new medications for treating infection with the hepatitis C virus (HCV): Harvoni cures up to 98% of patients with genotype 1 HCV. Viekira Pak cures 100% of those with genotype 1b HCV. Sovaldi cures 95% of those with genotype 2 HCV. With …